Norvir (Ritonavir)

Ritonavir blocks the HIV‑1 protease enzyme, preventing the cleavage of viral polyproteins needed for the formation of mature, infectious virus particles. By inhibiting this step, the drug reduces the production of functional virus and enhances the effectiveness of other antiretroviral agents.

The dosage of Norvir is individualized by the prescribing clinician based on the patient’s clinical condition, treatment regimen, and laboratory results. Only a qualified healthcare provider can determine the appropriate dose and schedule.

Safety data for ritonavir in pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare professional.

To request Norvir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ritonavir is often used as a pharmacokinetic booster for other protease inhibitors because of its strong CYP3A4 inhibition, which can increase the plasma levels of co‑administered drugs. Compared with newer protease inhibitors that have more favorable side‑effect profiles, ritonavir may have a higher incidence of gastrointestinal and metabolic adverse effects.

Norvir should be stored at ambient temperature, preferably below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency throughout its shelf life.

Norvir is taken orally, usually with food to improve tolerability. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include hepatotoxicity, pancreatitis, severe allergic reactions, QT interval prolongation, and metabolic disturbances such as hyperglycemia and lipodystrophy. Patients should be monitored regularly for liver function, cardiac rhythm, and metabolic parameters while on therapy.

Norvir is contraindicated in patients with known hypersensitivity to ritonavir or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment or in those taking medications that have a documented major interaction that cannot be safely managed.